` PPBT (Purple Biotech Ltd) vs Tel Aviv 355 Comparison - Alpha Spread

P
PPBT
vs
T
Tel Aviv 355

Over the past 12 months, PPBT has underperformed Tel Aviv 355, delivering a return of -81% compared to the Tel Aviv 355's +59% growth.

Stocks Performance
PPBT vs Tel Aviv 355

Loading
PPBT
Tel Aviv 355
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PPBT vs Tel Aviv 355

Loading
PPBT
Tel Aviv 355
Difference
www.alphaspread.com

Performance By Year
PPBT vs Tel Aviv 355

Loading
PPBT
Tel Aviv 355
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Purple Biotech Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Purple Biotech Ltd
Glance View

Market Cap
19.5m ILS
Industry
Pharmaceuticals

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

PPBT Intrinsic Value
2.94 ILS
Undervaluation 63%
Intrinsic Value
Price
P
Back to Top